ChiCTR2100049654 版本V1.1 版本创建时间2022/03/09 20:05:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100049654 

最近更新日期:

Date of Last Refreshed on:

2022-03-09 20:00:06 

注册时间:

Date of Registration:

2021-08-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下腰方肌阻滞运用于全髋关节置换术:罗哌卡因最低有效浓度的研究

Public title:

Ultrasound-guided quadratus lumborum block for total hip arthroplasty: a study of the minimum effective concentration of ropivacaine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下腰方肌阻滞运用于全髋关节置换术:罗哌卡因最低有效浓度的研究

Scientific title:

Ultrasound-guided quadratus lumborum block for total hip arthroplasty: a study of the minimum effective concentration of ropivacaine

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡建 

研究负责人:

杨静 

Applicant:

Hu Jian 

Study leader:

Yang Jing 

申请注册联系人电话:

Applicant telephone:

+86 13096136282

研究负责人电话:

Study leader's
telephone:

+86 18980602269

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1058939973@qq.com

研究负责人电子邮件:

Study leader's E-mail:

422963362@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital, Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019-831

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理委员会

Name of the ethic committee:

Biomedical Ethics Committee of West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-01-14 00:00:00

伦理委员会联系人:

曾智

Contact Name of the ethic committee:

Zeng Zhi

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院麻醉科

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Lane, Wuhou District

经费或物资来源:

国家自然科学基金(编号:81772130)

Source(s) of funding:

National Natural Science Foundation of China (No. 81772130)

研究疾病:

髋关节骨关节炎,股骨头坏死(Ficat IIIB或IV)和髋关节发育不良  

Target disease:

osteoarthritis of the hip, osteonecrosis of the femoral head (Ficat IIIB or IV), and developmental dysplasia of the hip.

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探究罗哌卡因用于全髋关节置换术超声引导下腰方肌阻滞的最低有效浓度。  

Objectives of Study:

To explore the minimum effective concentration of ropivacaine for ultrasound-guided quadratus lumborum block in total hip arthroplasty.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)18-80岁; 2)体重指数(BMI)为20-35 kg/m2; 3)美国麻醉师学会(ASA)II-III的功能状态; 4)初次单侧全髋关节置换术。

Inclusion criteria

1) 18-80 years of age; 2) body mass index (BMI) of 20-35 kg/m2; 3) an American Society of Anesthesiologists (ASA) functional status of II-III; 4) primary unilateral total hip arthroplasty.

排除标准:

1)髋关节强直; 2)已知对本研究中使用的药物过敏; 3)阿片类药物过量使用史; 4)有过量饮酒史; 5)认知障碍; 6)精神病; 7)公认的神经肌肉疾病; 8)既往髋关节开放手术史; 9)目标侧髋部患有其他神经性疾病; 10)无法进行口头交流。

Exclusion criteria:

1) hip ankylosis; 2) known allergy to the drugs used in this study; 3) a history of excessive opioid consumption; 4) a history of excessive alcohol consumption; 5) cognitive impairment; 6) psychiatric illness; 7) recognized neuromuscular disorder; 8) previous hip open surgery; 9) other neuropathic diseases of the hip on the target side; 10) inability to communicate verbally.

研究实施时间:

Study execute time:

From 2021-08-10 00:00:00 To 2021-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-08-10 00:00:00 To 2021-10-01 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

50

Group:

group A

Sample size:

干预措施:

腰方肌阻滞

干预措施代码:

Intervention:

quadratus lumborum block

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

腰方肌阻滞是否成功

指标类型:

主要指标

Outcome:

Whether the quadratus lumborum block was successful.

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

无随机方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

No random method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后即公开原始数据。试验的原始数据上传至中国临床试验注册中心的ResMan原始数据共享平台(IPD共享平台),http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be made public once the paper is published.The original data of the trial will be uploaded to the ResMan, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

同时采用病历记录表和电子管理系统进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Electronic Data Capture were used for data management simultaneously.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-08-07 08:29:30